HOUSTON - nvtip -- Respiratory Technology Corporation ("Restech") is pleased to announce the acquisition of the assets of Somna Therapeutics LLC. Somna provides medical devices for the treatment of laryngopharyngeal reflux (LPR) and extraesophageal acid reflux diseases. Their key product, the Reflux Band, is a non-pharmacologic, wearable device that prevents reflux into the larynx, pharynx, and lungs.

This transaction represents Restech's second significant acquisition since 2018 when it acquired the assets of Mederi Therapeutics LLC. According to Thomas Ball, Restech Vice President of Clinical Affairs, "Restech continues to expand its continuum of care for reflux related illnesses. Our core Dx-pH diagnostic product and Stretta endoscopic procedure are well respected among physicians, and our recently released PepsinCheck direct to consumer diagnostic test has been extremely well-received. With the anticipated re-launch of the Reflux Band, we will add another non-medicative reflux relief option. Globally, patients are eager to play an increasingly active role in their medical care, and Restech is there to empower them with the solutions they need."

More on nvtip.com

• Colbert Packaging Announces WBENC Recognition
• DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
• Akon City Cancelled: Primal Mogul Confirms Senegal Scraps $6B Smart City Plan for $1.2B Resort
• Assent Expands Executive Team to Accelerate Global Growth & Innovation
• The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge

About Somna Therapeutics LLC
Based in Germantown, Wisconsin, Somna Therapeutics LLC, was founded in 2012 by Tom Shannon, Nick Maris, Jeff Harris, and Reza Shaker, MD, in partnership with the Medical College of Wisconsin. Reflux Band was originally introduced as the Reza Band — named for its inventor, Reza Shaker, MD. Its name was changed to Reflux Band to better align the product with the condition it helps relieve — LPR due to acid reflux into the throat and lungs. The product is FDA Cleared and CE marked as a class I, over-the-counter non-pharmacologic LPR solution.

About Restech
Restech, formed in 2003 is based in Houston, Texas. We believe there is a better way to manage reflux. It all started in a meeting with world renowned gastroenterologists who told our engineers a little secret: the market needed a pH sensor that works outside of the esophagus. Our team accepted the challenge and launched the first real-time sensor that could function accurately in a non-liquid environment. Since then, we've been on a mission to rethink reflux, ensuring we understand the ins and outs of the disease state and industry. Although it is highly complex, we are passionate about bringing simple, effective reflux solutions to patients and clinicians around the world. Our rapid growth reflects our dedication and passion–developing and seeking out new products across the reflux diagnostic and therapeutic continuum from surgical to home health.

More on nvtip.com

• Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
• Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
• Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
• Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
• $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co